BioCentury
ARTICLE | Clinical News

Regulus reports Phase I data for antisense therapy RG-012

May 12, 2017 5:39 AM UTC

Regulus Therapeutics Inc. (NASDAQ:RGLS) reported preliminary data from a double-blind, placebo-controlled Phase I trial in 24 healthy volunteers showing that multiple ascending doses of Alport syndrome candidate RG-012 were well tolerated with no serious adverse events reported.

By mid-year, the company plans to start the Phase II HERA trial and a Phase I/II renal biopsy study, both of which will evaluate RG-012 in patients with Alport syndrome. Interim data from HERA are expected in mid-2018 and data from the renal biopsy study are expected by year end...

BCIQ Company Profiles

Regulus Therapeutics Inc.

BCIQ Target Profiles

MicroRNA-21 (miR-21)